ENT1 | Jotup

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Retrieved on:

일요일, 4월 7, 2024

Adenosine, Patient, Neoplasm, AACR, TILS, Therapy, Equilibrative nucleoside transporter 1, ENT1, Pharmaceutical industry

In preclinical studies, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, resulting in the restoration of T cell function and enhanced tumor cell killing.

Key Points:

In preclinical studies, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, resulting in the restoration of T cell function and enhanced tumor cell killing.
Due to its mechanism of action, EOS-984 holds potential as a combination partner beyond anti-PD-1 therapy, including other immuno-oncology agents, cell therapies, and bispecific T cell engagers.
EOS-984 is currently in the dose escalation portion of a Phase 1 trial in advanced malignancies.
Topline data from the Phase 1 trial is anticipated in the second half of 2024.

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on:

수요일, 3월 6, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points:

and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
“With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects.
We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024.
On December 7, 2023, iTeos announced the appointment of David K. Lee to the Company’s Board of Directors.

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Retrieved on:

화요일, 3월 5, 2024

Therapy, Equilibrative nucleoside transporter 1, ENT1, AACR, PM, Patient

WATERTOWN, Mass.

Key Points:

WATERTOWN, Mass.
and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1 (ENT1), at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California.
Date and Time: Sunday, April 7, 2024, 1:30 PM - 5:00 p.m. PT

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Retrieved on:

월요일, 1월 8, 2024

IO, ENT1, Survival, Place of birth, PD-1, Therapy, GSK, Lymphocyte, HNSCC, Patient, TIGIT, NSCLC, Equilibrative nucleoside transporter 1, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

Key Points:

and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.
“Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab.
The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials.
The Company continues to expect its cash balance to provide runway through 2026, which includes the initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.

PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders

Retrieved on:

금요일, 12월 1, 2023

PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997.

Key Points:

PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997.
RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics’ AI-enabled phenotypic screening platforms.
PsychoGenics intends to evaluate RO7117997 as a potential treatment for several psychiatric and neurological conditions, starting with sleep and seizure disorders.
Inhibition of ENT1 represents a novel approach for addressing a range of neuropsychiatric disorders.